Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Refractory Thyroid Cancer
NCT00381641Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in differentiated thyroid carcinoma (DTC) and medullary thyroid carcinoma (MTC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
differentiated thyroid carcinoma (DTC)medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00381641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381641.